Hikma cuts offer for Boehringer's U.S. generic drug unit by $535 million

(Reuters) - Hikma Pharmaceuticalssaid it would now pay $535 million less than its earlier offer to buy Boehringer Ingelheim's U.S. generic drugs business after due diligence revealed that the...